Thyroid Disorder Market Research Report - Global Forecast till 2027

Global Thyroid Disorder Market: Information by Type (Hypothyroidism and Hyperthyroidism), Treatment (Medications, Radioactive Iodine Therapy and Surgery), Route of Administration (Oral, Intravenous and others), End User (Hospitals, Clinics and others) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2027

ID: MRFR/Pharma/2031-CR | July 2019 | Region: Global | 118 pages

Please note that the assessment period of report has been updated from 2018-2025 to 2020-2027. Cordially fill the sample form for updated data.

Market overview


With the expected CAGR of 3.60%, the global thyroid disorder market is also likely to touch a 3,241.21 million USD mark by 2025. These figures are indeed up-and-coming and ensure that the market has vast scope in the coming future. The disorders that arise due to improper functioning of thyroid glands are referred to as thyroid disorders. This gland is located at the middle level of the lower neck and is responsible for the secretion of the hormone known as thyroid hormone. The primary function of this hormone is to regulate the activities related to metabolism in the body. If an individual suffers from thyroid disorders, it leads to an increased or decreased level of hormones responsible for metabolism in the body. Such elevation or decrease in thyroid disorder symptoms causes hypothyroidism, hyperthyroidism, and many more. The main elements driving the thyroid disorder market are the fact that people are getting more awareness about the thyroid disorder causes and the medical health policies, making them more aware of their health. But factors that restrict or push back the market are the pensive procedures involved are relatively high and also have known to cause side effects.


COVID-19 analysis 


The entire world has witnessed an unforgettable time with the COVID 19 pandemic attack. Lives for everyone have taken a turn. Businesses have been affected the most, and getting back to normal would take some time for sure. Even after utilizing resources and human resources, each company would require mentorship and guidance to ensure that they are on the correct track and cope with whatever they have lost in a short period. 


The reports prepared provide insights about all thin depth analyses carried out by the experts over the last few months. The reports have a particular focus on the effect that the pandemic has bought on the companies. This is one of those cost-effective measures that have expertise attached to them yet are budget-friendly. They also provide the current situation of the market in various countries.


Market Dynamics


Thyroid-related disorders have been increasing each year. Thyroid disorder causes include bad eating habits or other related factors. According to recent research, more than 12% of the total population in the united states is suffering thyroid-related disorder, which is, in fact, a considerable figure. It's just in the states, but other developed and developing countries like India, UK, and many more have also seen a similar rise in the figures. Hypothyroidism is prevalent in a developed region like the United Kingdom, where around 27.7% of the total population suffers from the same. Type increasing figures have given a boost to the thyroid disorder market size in the last few years. It has also been studied that thyroid-related disorders are even more common than diseases like cancer.


Regulatory implications


Marketing, production, and the distribution of the thyroid disorder market are regulated by FDA or food and drug administration. In Europe, it is controlled by EMA or European Medicines Agency. In a recent study, it has been revealed that FDA and EMA both have almost the same criteria for regulations of the products and services in the market. These organizations are being planned to make sure that drugs can be made available to people at many affordable rates. These keep a check of how the service and or products are being marketed and manufactured. The bodies that regulate the fact that the users with thyroid disorder symptoms get everything at affordable prices are not compromises on the quality have proved to bring sustainability and stability in the thyroid disorder market.


Segment overview


Various segments in which the market has been divided are


By type


By type, the thyroid disorder market is sub-divided into:


• Hypothyroidism


• Hyperthyroidism


Based on treatment


There is three subdivision in the thyroid gland disorders treatment market :


• Medications


• Surgery


• Radioactive iodine therapy


Based on the route of administration


There are a further three sub-divisions based on the route of administration. These are:


• Intravenous


• Oral


• Other


Based on end-user


These are further subdivided into three subtypes. These are:


• Clinics


• Hospitals


• Others


Regional analysis


The market is divided into the Americas, the Asia Pacific, the middle east, Africa, and Europe based in the regions. 


The Americas dominate the thyroid disorder market size, mainly because of the high population suffering from one of the other thyroid-related disorders. According to a survey conducted in the year 2016, almost 13 million people suffer from these disorders. There has been advancement in medicines and thyroid disorder treatment procedures for thyroid-related conditions as well. Moreover, awareness among the population has to lead to growth and the market too.


The region that bags the second place is that of Europe. An increase in the number of pharmaceutical companies that export their products outside Europe has contributed to the market's growth to a great extent. Research and the development of medicines for thyroid-related disorders have been a main task foremost in Europe. Not only this, but there has been a sharp increase in the investments made in pharmaceutical logistics, which is also a critical factor in the growth of the market in Europe as per the latest thyroid disorder case study.


The fastest-growing thyroid disorder market share is that of Asia Pacific, which can be considered the destinations outsourced for clinical trials, testing, and manufacturing of drugs. Sideways, third-party pharmaceutical companies are also looking to expand their business in developing countries like India, Singapore, China. 


Competitive landscape


Here is a list of the key contenders of the thyroid disorder market according to the latest thyroid disorder case studyPfizer Inc (US) can be considered the top-notch company that leads the thyroid disorder market. The companies that also have a significant role in the market are AbbVie Inc (US), Merck KGaA (Germany). Not to forget a few others that have emerged as influential players in the last few tears. There are Abbott Laboratories (US), GlaxoSmithKline PLC (UK), RLC Labs (US), and Mylan NV (US). As can be seen, most of the key players are from the united states. Reason being that it dominates the thyroid disorder treatment market for the highest population suffering from such diseases. The strategies that all of them have been following to reach today include product development, expansion, and innovation.


Recent developments


Recent development in the thyroid disorder market are


• In November 2015, a program that focuses on managing the daily routine of those having the life-long condition of hypothyroidism was launched by Abbie under Good Morning Hypothyroidism (GMH).


• In October 2016, ThyroTest was introduced by Abbott acquired Alere Inc., a service provider organization and a diagnostic device manufacturer introduced in the market, which is a test to detect hypothyroidism.


• In March 2018, an orally available tyrosine kinase inhibitor was discovered by Eisai.


• Also, in the same month, it was announced by Eisai Co Ltd and Merck about their strategic collar radiation. They are popularly called MSD after the collaboration.


• The commercialization of LENVIMA was also done in the year 2018.


Report overview


A market that is all set to reach a CAGR that equals a great figure is the global thyroid disorder market. While the population is experiencing an increased rate of thyroid disorders, the growth that the thyroid disorder market share has seen and is expected to see is tremendous. Rising awareness about the illness is another factor contributing to being the growth of the market. On the other hand, in developed or underdeveloped countries, the market's development is sluggish due to the availability of inadequate health facilities, high cost of thyroid gland disorders treatment market, and lack of awareness. The trend and growth of the market are increasing slowly but would take a little time. 



Frequently Asked Questions (FAQ) :


The global thyroid disorder market is predicted to touch USD 3,241.21 million by 2025.

The thyroid disorder market is predicted to grow at a 3.60% CAGR between 2016-2025.

The Americas is predicted to lead the thyroid disorder market during the forecast period.

Key competitors in the thyroid disorder market include Mylan, GlaxoSmithKline Plc, Abbott Laboratories, RLC Labs, Merck KGaA, AbbVie Inc., Pfizer Inc, and Allergan Inc.

It is most likely that hospitals will dominate the market.

Global Thyroid Disorder Market is set to witness a CAGR of 3.60% from 2018 to 2025. During the course of the review period, the market is expected to surpass a valuation of USD 3,241.21 Mn. The incidence rate has increased to a considerable extent. Thyroid is the root cause of various other illness such as fluctuation in metabolic hormone secretion, as hypothyroidism, hyperthyroidism, etc. The American Thyroid Association has revealed that more than 12% of the US population develops a thyroid disorder during their lifetime. A similar trend prevails across regions such as Western Europe and parts of Asia Pacific. As per the report submitted by the Thyroid Disease: Assessment and Management Draft of the National Institute for Health and Care Excellence, close to 27.2% of the total UK population was affected with hypothyroidism in 2017. There has been a steady rise in demand for thyroid therapeutics.


Increasing prevalence of associated conditions, rising awareness about thyroid disease, and favorable reimbursement policies are some of the factors supporting the growth of the global thyroid disorder market. In developing countries, the market proliferation is sluggish owing to factors such as poor healthcare penetration, high-cost of treatment and lack of healthcare programs. Many of the developing countries have massive pools of price-sensitive patients that show high reluctance towards expensive treatment options.


Segmental Analysis


The segmental analysis of the global thyroid disorder market is conducted on the basis on type, treatment, route of administration, end-user, and region.


By type, the market has been segmented hypothyroidism and hyperthyroidism. The hypothyroidism segment holds the dominant market share in terms of value. In 2017, the segment accounted for more than two-third share of the global thyroid disorder market and is expected to surge at 3.50% CAGR during the assessment period. The number of people diagnosed with hypothyroidism has been growing consistently. Individuals suffering from chronic diseases such as diabetes is more susceptible to hypothyroidism.


By treatment, the market has been segmented into medication, radioactive iodine therapy and surgery. The medication segment accounted for 79% market share in 2017 and is expected to remain highly attractive in 2019 and beyond. During the forecast period, the segment is projected to witness a CAGR of 3.71% and reach a market valuation in excess of USD 2,300 Mn. Development of effective drugs coupled with widespread availability of medication is supporting the growth of the segment. The radioactive iodine therapy is likely to retain the second largest market over 2022.


By route of administration, the market has been segmented into oral, intravenous, and others. In 2017, the oral segment accounted for a whopping 94.6% market share and is projected to witness a CAGR of 3.64% during the forecast period. Preference for oral route of administration is relative higher. This is because advantages such as low risk of side-effects, comparatively low dose, and good efficiency.


By end user, the market has been segmented into hospitals, clinics and others. The hospital segment accounts for the lion’s share of the market. In addition, the segment is expected to witness a CAGR of 3.89% during the forecast period. This can be attributed to factors such as growing patient influx, access to a robust healthcare service and increasing number of new hospitals.


Regional Analysis


On the basis of region, the market has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. In 2017, the Americas accounted for the largest market share. The market in Americas is currently valued at over USD 1,100 Mn and is likely to increase at a CAGR of 3.50% over 2022. This is primarily owing to the increased prevalence of thyroid disorders in countries such the U.S., Canada and Mexico. According to the American Association of Clinical Endocrinologists (AACE) survey, approximately 13 million Americans had thyroid disorders in 2016. The Americas is followed by Europe and Asia Pacific. While Europe is likely to retain is top position, Asia Pacific is projected to capture the strongest CAGR.


Competition Tracking


Some of the leading companies operating in the global thyroid disorder market are Allergan Inc., Pfizer Inc., AbbVie Inc., Merck KGaA, RLC Labs, Abbott Laboratories, GlaxoSmithKline Plc, and Mylan.

1 Report Prologue

2 Executive Summary

3 Market Introduction

3.1 Definition 18

3.2 Scope Of The Study 18

3.3 List Of Assumptions 19

3.4 Market Structure 19

4 Research Methodology

4.1 Research Process 21

4.2 Primary Research 21

4.3 Secondary Research 22

4.4 Market Size Estimation 23

4.5 Forecast Model 24

5 Market Dynamics

5.1 Introduction 26

5.2 Drivers 26

5.2.1 Increasing Prevalence Of Thyroid Diseases 26

5.2.2 Rising Awareness Of Thyroid 26

5.2.3 Favorable Reimbursement And Funding Policies 27

5.2.4 Drivers Impact Analysis 27

5.3 Restraint 28

5.3.1 High Cost Of Treatment Procedures Such As Radioactive Iodine (RAI) Therapy 28

5.3.2 Side-Effects Related To Available Therapeutics 28

5.3.3 Restraints Impact Analysis 28

5.4 Opportunity 29

5.4.1 Emerging Markets Of Asia-Pacific 29

5.5 Macroeconomic Indicators 29

6 Market Factor Analysis

6.1 Porter’s Five Forces Model 31

6.1.1 Threat Of New Entrants 32

6.1.2 Bargaining Power Of Suppliers 32

6.1.3 Threat Of Substitutes 32

6.1.4 Bargaining Power Of Buyers 32

6.1.5 Intensity Of Rivalry 32

7 Thyroid Disorder Market, By Type

7.1 Overview 34

7.1.1 Introduction 34

7.1.2 Hypothyroidism 35

7.1.3 Hyperthyroidism 36

8 Thyroid Disorder Market, By Treatment

8.1 Overview 38

8.1.1 Introduction 38

8.1.2 Medications 39

8.1.3 Radioactive Iodine Therapy 40

8.1.4 Surgery 41

9 Thyroid Disorder Market, By Route Of Administration

9.1 Overview 43

9.1.1 Oral 44

9.1.2 Intravenous 45

10 Thyroid Disorder Market, By End User

10.1 Overview 47

10.1.1 Hospitals 48

10.1.2 Clinics 49

11 Global Thyroid Disorder Market, By Region

11.1 Overview 51

11.2 Americas 52

Thyroid Disorder Market, By Type

Thyroid Disorder Market, By Treatment

Thyroid Disorder Market, By Route Of Administration

Thyroid Disorder Market, By End User

11.2.1 North America 55

Thyroid Disorder Market, By Type

Thyroid Disorder Market, By Treatment

Thyroid Disorder Market, By Route Of Administration

Thyroid Disorder Market, By End User

11.2.1.1 US 57

Thyroid Disorder Market, By Type

Thyroid Disorder Market, By Treatment

Thyroid Disorder Market, By Route Of Administration

Thyroid Disorder Market, By End User

11.2.1.2 Canada 58

Thyroid Disorder Market, By Type

Thyroid Disorder Market, By Treatment

Thyroid Disorder Market, By Route Of Administration

Thyroid Disorder Market, By End User

11.2.2 Latin America 60

Thyroid Disorder Market, By Type

Thyroid Disorder Market, By Treatment

Thyroid Disorder Market, By Route Of Administration

Thyroid Disorder Market, By End User

11.3 Europe 62

Thyroid Disorder Market, By Type

Thyroid Disorder Market, By Treatment

Thyroid Disorder Market, By Route Of Administration

Thyroid Disorder Market, By End User

11.3.1 Western Europe 64

Thyroid Disorder Market, By Type

Thyroid Disorder Market, By Treatment

Thyroid Disorder Market, By Route Of Administration

Thyroid Disorder Market, By End User

11.3.1.1 Germany 66

Thyroid Disorder Market, By Type

Thyroid Disorder Market, By Treatment

Thyroid Disorder Market, By Route Of Administration

Thyroid Disorder Market, By End User

11.3.1.2 France 68

Thyroid Disorder Market, By Type

Thyroid Disorder Market, By Treatment

Thyroid Disorder Market, By Route Of Administration

Thyroid Disorder Market, By End User

11.3.1.3 UK 69

Thyroid Disorder Market, By Type

Thyroid Disorder Market, By Treatment

Thyroid Disorder Market, By Route Of Administration

Thyroid Disorder Market, By End User

11.3.1.4 Italy 71

Thyroid Disorder Market, By Type

Thyroid Disorder Market, By Treatment

Thyroid Disorder Market, By Route Of Administration

Thyroid Disorder Market, By End User

11.3.1.5 Spain 73

Thyroid Disorder Market, By Type

Thyroid Disorder Market, By Treatment

Thyroid Disorder Market, By Route Of Administration

Thyroid Disorder Market, By End User

11.3.1.6 Rest Of Western Europe 74

Thyroid Disorder Market, By Type

Thyroid Disorder Market, By Treatment

Thyroid Disorder Market, By Route Of Administration

Thyroid Disorder Market, By End User

11.3.2 Eastern Europe 76

Thyroid Disorder Market, By Type

Thyroid Disorder Market, By Treatment

Thyroid Disorder Market, By Route Of Administration

Thyroid Disorder Market, By End User

11.4 Asia-Pacific 78

Thyroid Disorder Market, By Type

Thyroid Disorder Market, By Treatment

Thyroid Disorder Market, By Route Of Administration

Thyroid Disorder Market, By End User

11.4.1 Japan 81

Thyroid Disorder Market, By Type

Thyroid Disorder Market, By Treatment

Thyroid Disorder Market, By Route Of Administration

Thyroid Disorder Market, By End User

11.4.2 China 82

Thyroid Disorder Market, By Type

Thyroid Disorder Market, By Treatment

Thyroid Disorder Market, By Route Of Administration

Thyroid Disorder Market, By End User

11.4.3 India 84

Thyroid Disorder Market, By Type

Thyroid Disorder Market, By Treatment

Thyroid Disorder Market, By Route Of Administration

Thyroid Disorder Market, By End User

11.4.4 South Korea 86

Thyroid Disorder Market, By Type

Thyroid Disorder Market, By Treatment

Thyroid Disorder Market, By Route Of Administration

Thyroid Disorder Market, By End User

11.4.5 Australia 87

Thyroid Disorder Market, By Type

Thyroid Disorder Market, By Treatment

Thyroid Disorder Market, By Route Of Administration

Thyroid Disorder Market, By End User

11.4.6 Rest Of Asia-Pacific 89

Thyroid Disorder Market, By Type

Thyroid Disorder Market, By Treatment

Thyroid Disorder Market, By Route Of Administration

Thyroid Disorder Market, By End User

11.5 Middle East & Africa 91

Thyroid Disorder Market, By Type

Thyroid Disorder Market, By Treatment

Thyroid Disorder Market, By Route Of Administration

Thyroid Disorder Market, By End User

11.5.1 Middle East 93

Thyroid Disorder Market, By Type

Thyroid Disorder Market, By Treatment

Thyroid Disorder Market, By Route Of Administration

Thyroid Disorder Market, By End User

11.5.2 Africa 95

Thyroid Disorder Market, By Type

Thyroid Disorder Market, By Treatment

Thyroid Disorder Market, By Route Of Administration

Thyroid Disorder Market, By End User

12 Competitive Landscape

12.1 Company Market Share Analysis 98

12.1.1 Introduction 98

13 Company Profiles

13.1 Pfizer Inc 100

13.1.1 Company Overview 100

13.1.2 Financial Overview 100

13.1.3 Products/Services Offered 101

13.1.4 Key Developments 101

13.1.5 SWOT Analysis 101

13.1.6 Key Strategy 101

13.2 Allergan Inc. 102

13.2.1 Company Overview 102

13.2.2 Financial Overview 102

13.2.3 Products/Services Offered 103

13.2.4 Key Developments 103

13.2.5 SWOT Analysis 103

13.2.6 Key Strategy 103

13.3 AbbVie Inc. 104

13.3.1 Company Overview 104

13.3.2 Financial Overview 104

13.3.3 Products/Services Offering 105

13.3.4 Key Developments 105

13.3.5 SWOT Analysis 105

13.3.6 Key Strategy 105

13.4 Merck KGaA 106

13.4.1 Company Overview 106

13.4.2 Financial Overview 106

13.4.3 Products/Services Offering 107

13.4.4 Key Developments 107

13.4.5 SWOT Analysis 107

13.4.6 Key Strategy 107

13.5 RLC Labs 108

13.5.1 Company Overview 108

13.5.2 Financial Overview 108

13.5.3 Products/Services Offered 108

13.5.4 SWOT Analysis 108

13.5.5 Key Developments 108

13.5.6 Key Strategy 108

13.6 Abbott Laboratories 109

13.6.1 Company Overview 109

13.6.2 Financial Overview 109

13.6.3 Products/Services Offered 110

13.6.4 Key Developments 110

13.6.5 SWOT Analysis 110

13.6.6 Key Strategy 110

13.7 GlaxoSmithKline PLC 111

13.7.1 Company Overview 111

13.7.2 Financial Overview 111

13.7.3 Products/Services Offered 112

13.7.4 Key Developments 112

13.7.5 SWOT Analysis 112

13.7.6 Key Strategy 112

13.8 Mylan 113

13.8.1 Company Overview 113

13.8.2 Financial Overview 113

13.8.3 Products/Services Offered 114

13.8.4 Key Developments 114

13.8.5 SWOT Analysis 114

13.8.6 Key Strategy 114

14 Appendix

14.1 Discussion Blue Print 116

15 List Of Tables

TABLE 1 MARKET SYNOPSIS 16

TABLE 2 LIST OF ASSUMPTIONS 19

TABLE 3 GLOBAL THYROID DISORDER MARKET, BY TYPE, 2020–2027 (USD MILLION) 35

TABLE 4 GLOBAL THYROID DISORDER MARKET FOR HYPOTHYROIDISM, BY REGION, 2020–2027 (USD MILLION) 35

TABLE 5 GLOBAL THYROID DISORDER MARKET FOR HYPERTHYROIDISM, BY REGION, 2020–2027 (USD MILLION) 36

TABLE 6 GLOBAL THYROID DISORDER MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 39

TABLE 7 GLOBAL THYROID DISORDER MARKET FOR MEDICATIONS, BY REGION, 2020–2027 (USD MILLION) 39

TABLE 8 GLOBAL THYROID DISORDER MARKET FOR RADIOACTIVE IODINE THERAPY, BY REGION, 2020–2027 (USD MILLION) 40

TABLE 9 GLOBAL THYROID DISORDER MARKET FOR SURGERY, BY REGION, 2020–2027 (USD MILLION) 41

TABLE 10 GLOBAL THYROID DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 44

TABLE 11 GLOBAL THYROID DISORDER MARKET FOR ORAL, BY REGION, 2020–2027 (USD MILLION) 44

TABLE 12 GLOBAL THYROID DISORDER MARKET FOR INTRAVENOUS, BY REGION, 2020–2027 (USD MILLION) 45

TABLE 13 GLOBAL THYROID DISORDER MARKET, BY END USER, 2020–2027 (USD MILLION) 48

TABLE 14 GLOBAL THYROID DISORDER MARKET FOR HOSPITALS, BY REGION, 2020–2027 (USD MILLION) 48

TABLE 15 GLOBAL THYROID DISORDER MARKET FOR CLINICS, BY REGION, 2020–2027 (USD MILLION) 49

TABLE 16 GLOBAL THYROID DISORDER MARKET, BY REGION, 2020–2027 (USD MILLION) 51

TABLE 17 AMERICAS: THYROID DISORDER MARKET, BY REGION, 2020–2027 (USD MILLION) 53

TABLE 18 AMERICAS: THYROID DISORDER MARKET, BY TYPE, 2020–2027 (USD MILLION) 53

TABLE 19 AMERICAS: THYROID DISORDER MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 54

TABLE 20 AMERICAS: THYROID DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 54

TABLE 21 AMERICAS: THYROID DISORDER MARKET, BY END USER 2020–2027 (USD MILLION) 54

TABLE 22 NORTH AMERICA: THYROID DISORDER MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 55

TABLE 23 NORTH AMERICA: THYROID DISORDER MARKET, BY TYPE, 2020–2027 (USD MILLION) 55

TABLE 24 NORTH AMERICA: THYROID DISORDER MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 55

TABLE 25 NORTH AMERICA: THYROID DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 56

TABLE 26 NORTH AMERICA: THYROID DISORDER MARKET, BY END USER 2020–2027 (USD MILLION) 56

TABLE 27 US: THYROID DISORDER MARKET, BY TYPE, 2020–2027 (USD MILLION) 57

TABLE 28 US: THYROID DISORDER MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 57

TABLE 29 US: THYROID DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 57

TABLE 30 US: THYROID DISORDER MARKET, BY END USER 2020–2027 (USD MILLION) 58

TABLE 31 CANADA: THYROID DISORDER MARKET, BY TYPE, 2020–2027 (USD MILLION) 58

TABLE 32 CANADA: THYROID DISORDER MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 59

TABLE 33 CANADA: THYROID DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 59

TABLE 34 CANADA: THYROID DISORDER MARKET, BY END USER 2020–2027 (USD MILLION) 60

TABLE 35 LATIN AMERICA: THYROID DISORDER MARKET, BY TYPE, 2020–2027 (USD MILLION) 60

TABLE 36 LATIN AMERICA: THYROID DISORDER MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 60

TABLE 37 LATIN AMERICA: THYROID DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 61

TABLE 38 LATIN AMERICA: THYROID DISORDER MARKET, BY END USER 2020–2027 (USD MILLION) 61

TABLE 39 EUROPE: THYROID DISORDER MARKET, BY REGION, 2020–2027 (USD MILLION) 62

TABLE 40 EUROPE: THYROID DISORDER MARKET, BY TYPE, 2020–2027 (USD MILLION) 63

TABLE 41 EUROPE: THYROID DISORDER MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 63

TABLE 42 EUROPE: THYROID DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 63

TABLE 43 EUROPE: THYROID DISORDER MARKET, BY END USER 2020–2027 (USD MILLION) 64

TABLE 44 WESTERN EUROPE: THYROID DISORDER MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 64

TABLE 45 WESTERN EUROPE: THYROID DISORDER MARKET, BY TYPE, 2020–2027 (USD MILLION) 65

TABLE 46 WESTERN EUROPE: THYROID DISORDER MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 65

TABLE 47 WESTERN EUROPE: THYROID DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 65

TABLE 48 WESTERN EUROPE: THYROID DISORDER MARKET, BY END USER 2020–2027 (USD MILLION) 66

TABLE 49 GERMANY: THYROID DISORDER MARKET, BY TYPE, 2020–2027 (USD MILLION) 66

TABLE 50 GERMANY: THYROID DISORDER MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 67

TABLE 51 GERMANY: THYROID DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 67

TABLE 52 GERMANY: THYROID DISORDER MARKET, BY END USER 2020–2027 (USD MILLION) 67

TABLE 53 FRANCE: THYROID DISORDER MARKET, BY TYPE, 2020–2027 (USD MILLION) 68

TABLE 54 FRANCE: THYROID DISORDER MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 68

TABLE 55 FRANCE: THYROID DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 69

TABLE 56 FRANCE: THYROID DISORDER MARKET, BY END USER 2020–2027 (USD MILLION) 69

TABLE 57 UK: THYROID DISORDER MARKET, BY TYPE, 2020–2027 (USD MILLION) 69

TABLE 58 UK: THYROID DISORDER MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 70

TABLE 59 UK: THYROID DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 70

TABLE 60 UK: THYROID DISORDER MARKET, BY END USER 2020–2027 (USD MILLION) 71

TABLE 61 ITALY: THYROID DISORDER MARKET, BY TYPE, 2020–2027 (USD MILLION) 71

TABLE 62 ITALY: THYROID DISORDER MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 72

TABLE 63 ITALY: THYROID DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 72

TABLE 64 ITALY: THYROID DISORDER MARKET, BY END USER 2020–2027 (USD MILLION) 72

TABLE 65 SPAIN: THYROID DISORDER MARKET, BY TYPE, 2020–2027 (USD MILLION) 73

TABLE 66 SPAIN: THYROID DISORDER MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 73

TABLE 67 SPAIN: THYROID DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 74

TABLE 68 SPAIN: THYROID DISORDER MARKET, BY END USER 2020–2027 (USD MILLION) 74

TABLE 69 REST OF WESTERN EUROPE: THYROID DISORDER MARKET, BY TYPE, 2020–2027 (USD MILLION) 74

TABLE 70 REST OF WESTERN EUROPE: THYROID DISORDER MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 75

TABLE 71 REST OF WESTERN EUROPE: THYROID DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 75

TABLE 72 REST OF WESTERN EUROPE: THYROID DISORDER MARKET, BY END USER 2020–2027 (USD MILLION) 76

TABLE 73 EASTERN EUROPE: THYROID DISORDER MARKET, BY TYPE, 2020–2027 (USD MILLION) 76

TABLE 74 EASTERN EUROPE: THYROID DISORDER MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 76

TABLE 75 EASTERN EUROPE: THYROID DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 77

TABLE 76 EASTERN EUROPE: THYROID DISORDER MARKET, BY END USER 2020–2027 (USD MILLION) 77

TABLE 77 ASIA-PACIFIC: THYROID DISORDER MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 79

TABLE 78 ASIA-PACIFIC: THYROID DISORDER MARKET, BY TYPE, 2020–2027 (USD MILLION) 79

TABLE 79 ASIA-PACIFIC: THYROID DISORDER MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 80

TABLE 80 ASIA-PACIFIC: THYROID DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 80

TABLE 81 ASIA-PACIFIC: THYROID DISORDER MARKET, BY END USER 2020–2027 (USD MILLION) 80

TABLE 82 JAPAN: THYROID DISORDER MARKET, BY TYPE, 2020–2027 (USD MILLION) 81

TABLE 83 JAPAN: THYROID DISORDER MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 81

TABLE 84 JAPAN: THYROID DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 82

TABLE 85 JAPAN: THYROID DISORDER MARKET, BY END USER 2020–2027 (USD MILLION) 82

TABLE 86 CHINA: THYROID DISORDER MARKET, BY TYPE, 2020–2027 (USD MILLION) 82

TABLE 87 CHINA: THYROID DISORDER MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 83

TABLE 88 CHINA: THYROID DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 83

TABLE 89 CHINA: THYROID DISORDER MARKET, BY END USER 2020–2027 (USD MILLION) 84

TABLE 90 INDIA: THYROID DISORDER MARKET, BY TYPE, 2020–2027 (USD MILLION) 84

TABLE 91 INDIA; THYROID DISORDER MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 84

TABLE 92 INDIA: THYROID DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 85

TABLE 93 INDIA: THYROID DISORDER MARKET, BY END USER 2020–2027 (USD MILLION) 85

TABLE 94 SOUTH KOREA: THYROID DISORDER MARKET, BY TYPE, 2020–2027 (USD MILLION) 86

TABLE 95 SOUTH KOREA: THYROID DISORDER MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 86

TABLE 96 SOUTH KOREA: THYROID DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 86

TABLE 97 SOUTH KOREA: THYROID DISORDER MARKET, BY END USER 2020–2027 (USD MILLION) 87

TABLE 98 AUSTRALIA: THYROID DISORDER MARKET, BY TYPE, 2020–2027 (USD MILLION) 87

TABLE 99 AUSTRALIA: THYROID DISORDER MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 88

TABLE 100 AUSTRALIA: THYROID DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 88

TABLE 101 AUSTRALIA: THYROID DISORDER MARKET, BY END USER 2020–2027 (USD MILLION) 88

TABLE 102 REST OF ASIA-PACIFIC: THYROID DISORDER MARKET, BY TYPE, 2020–2027 (USD MILLION) 89

TABLE 103 REST OF ASIA-PACIFIC: THYROID DISORDER MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 89

TABLE 104 REST OF ASIA-PACIFIC: THYROID DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 90

TABLE 105 REST OF ASIA-PACIFIC: THYROID DISORDER MARKET, BY END USER 2020–2027 (USD MILLION) 90

TABLE 106 MIDDLE EAST AND AFRICA: THYROID DISORDER MARKET, BY REGION, 2020–2027 (USD MILLION) 91

TABLE 107 MIDDLE EAST AND AFRICA: THYROID DISORDER MARKET, BY TYPE, 2020–2027 (USD MILLION) 92

TABLE 108 MIDDLE EAST AND AFRICA: THYROID DISORDER MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 92

TABLE 109 MIDDLE EAST AND AFRICA: THYROID DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 92

TABLE 110 MIDDLE EAST AND AFRICA: THYROID DISORDER MARKET, BY END USER 2020–2027 (USD MILLION) 93

TABLE 111 MIDDLE EAST: THYROID DISORDER MARKET, BY TYPE, 2020–2027 (USD MILLION) 93

TABLE 112 MIDDLE EAST: THYROID DISORDER MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 94

TABLE 113 MIDDLE EAST: THYROID DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 94

TABLE 114 MIDDLE EAST: THYROID DISORDER MARKET, BY END USER 2020–2027 (USD MILLION) 94

TABLE 115 AFRICA: THYROID DISORDER MARKET, BY TYPE, 2020–2027 (USD MILLION) 95

TABLE 116 AFRICA: THYROID DISORDER MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 95

TABLE 117 AFRICA; THYROID DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 96

TABLE 118 AFRICA: THYROID DISORDER MARKET, BY END USER 2020–2027 (USD MILLION) 96

16 List Of Figures

FIGURE 1 GLOBAL THYROID DISORDER MARKET: MARKET STRUCTURE 19

FIGURE 2 RESEARCH PROCESS OF MRFR 21

FIGURE 3 TOP-DOWN & BOTTOM-UP APPROACHES 24

FIGURE 4 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL THYROID DISORDER MARKET 26

FIGURE 5 DRIVERS IMPACT ANALYSIS: GLOBAL THYROID DISORDER MARKET 27

FIGURE 6 RESTRAINTS IMPACT ANALYSIS: GLOBAL THYROID DISORDER MARKET 28

FIGURE 7 PORTER’S FIVE FORCES MODEL: GLOBAL THYROID DISORDER MARKET 31

FIGURE 8 GLOBAL THYROID DISORDER MARKET, BY TYPE, 2020 (%) 34

FIGURE 9 GLOBAL THYROID DISORDER MARKET, BY TYPE, 2020 AND 2027 34

FIGURE 10 GLOBAL THYROID DISORDER MARKET, BY TREATMENT, 2020 (%) 38

FIGURE 11 GLOBAL THYROID DISORDER MARKET, BY TREATMENT, 2020 AND 2027 38

FIGURE 12 GLOBAL THYROID DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2020 (%) 43

FIGURE 13 GLOBAL THYROID DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2020 AND 2027 43

FIGURE 14 GLOBAL THYROID DISORDER MARKET, BY END USER, 2020 (%) 47

FIGURE 15 GLOBAL THYROID DISORDER MARKET, BY END USER, 2020 AND 2027 47

FIGURE 16 GLOBAL THYROID DISORDER MARKET, BY REGION, 2020 AND 2027 (USD MILLION) 51

FIGURE 17 GLOBAL THYROID DISORDER MARKET, BY REGION, 2020 (%) 52

FIGURE 18 AMERICAS: THYROID DISORDER MARKET SHARE, BY REGION, 2020 (%) 53

FIGURE 19 EUROPE: THYROID DISORDER MARKET SHARE, BY REGION, 2020 (%) 62

FIGURE 20 ASIA-PACIFIC: THYROID DISORDER MARKET SHARE, BY COUNTRY, 2020 (%) 78

FIGURE 21 MIDDLE EAST AND AFRICA: THYROID DISORDER MARKET SHARE, BY REGION, 2020 (%) 91

FIGURE 22 GLOBAL THYROID DISORDER MARKET, MARKET SHARE ANALYSIS 2020 (%) 98

Competitive Landscape:


The global thyroid disorder market is characterized by the presence of many global, regional, and local vendors. The market is highly competitive with all players competing to gain the market share. Intense competition, rapid advances in technology, frequent changes in government policies, and environmental regulations are key factors that confront the market growth. The vendors compete based on cost, quality, and reliability. It is decisive for vendors to provide cost-efficient and high-quality products, to survive and succeed in an intensely competitive market environment.


The growth of market vendors is dependent on market conditions, government support, and industry development. Thus, vendors should focus on expanding geographically and improving their products. They primarily focus on the development of novel products. Although international players are dominating the market, regional and foreign players with small market shares also have a presence. The international players are likely to strengthen their presence worldwide through acquisitions during the forecast period. It has also been forecast that improvement of the global economic scenario combined with efforts to enhance infrastructure in emerging nations, is fueling the market growth, thereby making it an ideal time for new products and to increase the global market share.


Vendors with better technical and financial resources can develop innovative products. Therefore, vendors must develop new technologies and stay abreast of emerging technologies that could affect the continuing competitiveness in the market.


AbbVie Inc. has a vast product portfolio in the global thyroid disorder market. AbbVie Inc. is one of the leading pharmaceutical companies and is highly focused on R&D to target difficult-to-cure diseases. The company constantly works to create solutions that go beyond treating the illness and have a positive impact on patients’ lives, on societies, and on science itself.


Merck KGaA is another major company in the market and focuses on bringing health and wellness to individuals and communities worldwide. It is committed in advancing the health of families with its diversified portfolio of products and services to mainly focus on women health, fertility, and diagnostic products. It is one of the leading pharmaceutical companies which has a varied range of products in healthcare.